Asset
AMPRELOXETINE
Theravance Biopharma Inc. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01458340 | phase2 | completed | 2011-12-01 | 2013-10-01 | Theravance Biopharma | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| NCT03432793 | phase1 | completed | 2018-02-28 | 2018-04-21 | Theravance Biopharma | Drug-Drug Interaction (DDI) Study for TD-9855 |
| NCT01924143 | phase1 | completed | 2013-10-01 | 2013-11-01 | Theravance Biopharma | TD-9855 Mass Balance Study |
| NCT02705755 | phase2 | completed | 2017-09-09 | 2018-07-24 | Theravance Biopharma | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) |
FDA applications (0)
This company has no applications containing this asset.